Pyxis Oncology, Inc. (PYXS)
3.49
-0.40
(-10.28%)
USD |
NASDAQ |
Sep 09, 14:40
Pyxis Oncology Debt to Equity Ratio : 1.559 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.559 |
| March 31, 2026 | 0.5839 |
| December 31, 2025 | 0.3496 |
| September 30, 2025 | 0.2773 |
| June 30, 2025 | 0.2221 |
| March 31, 2025 | 0.1924 |
| December 31, 2024 | 0.1673 |
| September 30, 2024 | 0.1337 |
| June 30, 2024 | 0.1229 |
| March 31, 2024 | 0.1128 |
| December 31, 2023 | 0.1697 |
| Date | Value |
|---|---|
| September 30, 2023 | 0.1567 |
| June 30, 2023 | 0.1463 |
| March 31, 2023 | 0.1331 |
| December 31, 2022 | 0.1177 |
| September 30, 2022 | 0.0851 |
| June 30, 2022 | 0.074 |
| March 31, 2022 | 0.00 |
| December 31, 2021 | 0.0006 |
| September 30, 2021 | 0.0027 |
| December 31, 2020 | 0.1239 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| ACADIA Pharmaceuticals, Inc. | 0.0565 |
| Alnylam Pharmaceuticals, Inc. | 2.206 |
| Anika Therapeutics, Inc. | 0.1839 |
| Savara, Inc. | 0.2117 |
| Vericel Corp. | 0.2556 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 54.92M |
| Total Liabilities (Quarterly) | 43.48M |
| Shareholders Equity (Quarterly) | 11.44M |
| Current Ratio | 1.337 |
| Net Debt Paydown Yield | 0.21% |